CORONA Remedies Limited (CORONA) announced its unaudited financial results for Q1FY27, delivering robust revenue and resilient margins, supported by consistent brand-building and enhanced operational efficiencies. The company reported a revenue of ₹422.4 Cr for Q1FY27, registering a growth of 21.9% Y-o-Y, driven by execution excellence and focused brand-building initiatives.

Financial Performance

The Profit After Tax (PAT) for Q1FY27 stood at ₹60.1 Cr, a growth of 30.1% Y-o-Y. PAT margins for Q1FY27 stood at 14.2%, an increase of 90 bps Y-o-Y. The EBITDA for the quarter was ₹93.1 Cr, showing a 33.5% Y-o-Y growth. The EBITDA margin improved to 22.0% from 20.1% in the same period last year.

Key Business Highlights

CORONA continues to be the fastest-growing company among the top 30 companies of the Indian Pharma Market (IPM) for the last 6 consecutive months, as per MAT June ’26. The company has also inaugurated and initiated the commercialization of its EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad on June 30, 2026. Additionally, the integration of the acquired brand Wokadine is progressing smoothly from the supply and distribution perspectives.

Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “Q1 FY27 shows our commitment to consistent growth with operational excellence and brand building. With robust revenue growth and market rank improvement, we see positive outcomes of the strategies in place. We aim to move steadfast with our aligned focus on core therapies such as Women’s Healthcare, Cardio-diabetes, Pain Management, and Urology. We are also strengthening ourselves in Infertility and Biosimilar segments.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA gains 21.6% over three months and trades near its 52-week highs. The PEG of 2.33 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. The stock trades at 95% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.33 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

CORONA Remedies Limited has announced the inauguration and commercialisation of its state-of-the-art EU-GMP approved Hormone Manufacturing Facility in Bhayla, Ahmedabad. This facility marks a significant milestone in the company’s journey towards building globally benchmarked pharmaceutical manufacturing capabilities. The facility was inaugurated by Chairman, Dr. K. L. Mehta, alongside long-serving women employees of the organisation, symbolising CORONA’s enduring commitment to women’s health and the invaluable contribution of women in shaping the company’s success.

Responding to the Growing Need for Women’s Healthcare

As global attention towards women’s healthcare continues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fertility care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceutical manufacturing has become more critical than ever. Recognising this evolving need, CORONA Remedies has established one of India’s most advanced dedicated hormone manufacturing facilities, strengthening its capabilities to serve both domestic and international markets.

A Purpose-Built Manufacturing Ecosystem

Unlike conventional pharmaceutical manufacturing plants, dedicated hormone manufacturing requires complete segregation of operations, precision environmental controls, specialised containment technologies and highly trained personnel to ensure safe handling of potent hormone active pharmaceutical ingredients (APIs). CORONA’s integrated manufacturing platform supports multiple dosage forms—including tablets, soft gel capsules, ointments and gels—within a single specialised manufacturing ecosystem, enabling the company to cater to a broad spectrum of women’s healthcare therapies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA gains 26.5% over three months and trades near its 52-week highs. The PEG of 2.19 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.2x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 11 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.19 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

CORONA Remedies Limited (CORONA) has achieved significant milestones with the receipt of European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla in Ahmedabad. These accreditations further strengthen CORONA’s global manufacturing and quality credentials, reaffirming its commitment to world-class quality systems, scientific excellence, and manufacturing capabilities aligned with international standards.

Accelerated Global Expansion

Achieved with exceptional speed, these accreditations reflect CORONA’s strong quality culture, robust compliance framework, and operational excellence, marking a defining step in its journey to become a globally trusted partner in Hormone & other therapies. Commenting on the same, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited said, “We view this accreditation as a reflection of our unwavering commitment to quality and our philosophy of “One World. One Quality.” By adopting uniform global practices, we aim to serve both the Indian market and other regulated/semi-regulated markets from this facility.

Strategic Vision

Backed by strong scientific expertise, rapidly expanding manufacturing capabilities, and a clear strategic vision, CORONA remains committed to advancing accessible, high-quality healthcare in India while taking its Hormone portfolio to global markets — driven by our belief: “THINK HORMONE… THINK CORONA.”

As CORONA Remedies Limited continues to grow, these EU-GMP accreditations position the company as a leader in the pharmaceutical industry, capable of meeting the highest international standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA posts a 3.9% three-month gain, but softens in the last few weeks. The business compounds revenue at 16.7% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.7% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 16.7% and profits at 29.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of CORONA Remedies Limited.